Ventas, Inc. VTR reported first-quarter 2024 normalized funds from operations (FFO) per share of 78 cents, beating the Zacks Consensus Estimate of 74 cents. The reported figure increased 5.4% from the prior-year quarter’s tally. Results reflect better-than-anticipated revenues. Also, Ventas’ same-store cash net operating income (NOI) increased year over year on strong performance across the portfolio, except for triple-net leased properties. It has also raised its 2024 outlook. VTR clocked in revenues of $1.20 billion in the first quarter, surpassing the Zacks Consensus Estimate of $1.16 billion. Also, the figure increased 11.4% on a year-over-year basis. Per Debra A. Cafaro, chairman and CEO of Ventas, “2024 is off to a strong start, led by continued organic growth in our advantaged senior housing operating portfolio (“SHOP”), as we execute against our strategy. Demand-driven accelerating occupancy in SHOP drove our performance in the quarter, as the unprecedented multiyear growth opportunity in senior housing continues to build." Quarter in Detail In the reported quarter, same-store cash NOI for the total property portfolio (1,093 assets) increased 6.7% to $441.4 million from the prior-year quarter. Segment-wise, the same-store cash NOI for the SHOP portfolio (477 assets) climbed 15.2% year over year to $183.4 million, led by the U.S. communities. Revenues per occupied room (RevPOR) growth of 4.7% resulted in a margin expansion of 170 basis points (bps), aiding the rise in the segment’s same-store cash NOI. The same-store average occupancy expanded 240 bps year over year to 84.6% in the first quarter for the SHOP portfolio. For the outpatient medical and research portfolio (341 assets), same-store cash NOI improved 4.9% year over year to $129.3 million. The uptick was backed by continued strong performance in the outpatient medical portfolio that witnessed same-store cash NOI growth of more than 4%. The triple-net leased portfolio’s (275 assets) same-store cash NOI fell 2% year over year to $128.6 million. Balance Sheet Position Ventas exited first-quarter 2024 with cash and cash equivalents of $632.4 million, up from $508.8 million as of Dec 31, 2023. Moreover, it ended the quarter with $3.36 billion of liquidity and a net debt to further adjusted EBITDA ratio of 6.7. 2024 Outlook Ventas raised its guidance for 2024. It now expects 2024 normalized FFO per share in the range of $3.10-$3.18, revised from $3.07-$3.18 stated earlier. The Zacks Consensus Estimate for the same is currently pegged at $3.15, which lies within the guided range. The total same-store cash NOI growth is now estimated between 6% and 8%, up from 5.0-7.5% projected earlier. The SHOP segment's same-store cash NOI is now anticipated to be between 12% and 16%, higher than 10-15% from the prior guidance. The Outpatient Medical and Research Portfolio segment's same-store cash NOI is now expected in the range of 2.50-3.25% from 2.25-3.25%, while the estimation for triple-net leased same-store cash NOI was changed to 1.25-2.00% from 1-2%. Ventas currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Ventas, Inc. Price, Consensus and EPS Surprise Ventas, Inc. Price, Consensus and EPS Surprise Ventas, Inc. price-consensus-eps-surprise-chart | Ventas, Inc. Quote Performance of Other REITs Boston Properties Inc.’s BXP first-quarter 2024 funds from operations (FFO) per share of $1.73 was in line with the Zacks Consensus Estimate. The reported figure remained unchanged year over year. BXP’s quarterly results reflect better-than-anticipated revenues on healthy leasing activity. However, higher interest expenses during the quarter acted as a dampener. BXP also lowered its guidance for 2024 FFO per share. Healthpeak Properties, Inc. DOC reported first-quarter 2024 FFO as adjusted per share of 45 cents, beating the Zacks Consensus Estimate by a penny. The reported figure rose 7.1% from the prior-year quarter. Results reflect better-than-anticipated revenues. Moreover, growth in total merger-combined same-store cash (adjusted) NOI was witnessed across the portfolio. The company also revised its 2024 outlook. Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ventas, Inc. (VTR):Free Stock Analysis Report Boston Properties, Inc. (BXP):Free Stock Analysis Report Healthpeak Properties, Inc. (DOC):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Ventas (VTR) Q1 FFO Beats Estimates on Higher Same-Store NOI
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...